Perrigo Corp (PRGO) - Long-Term Debt to Capital Coefficient

Perrigo Corp - graphic logo of issuer PRGO

Perrigo Company plc (PRGO) dominates the OTC segment, leveraging a pipeline of affordable generics and an extensive retail network to drive margin growth. This price chart confirms its status as a reliable B2B partner producing medications for the largest pharmacy brands. The indicator stands at 1.33, underscoring the resilience of a closed private label ecosystem protected from external players by stringent FDA requirements.

Perrigo Company PLC (PRGO): Long-Term Debt to Equity from 07/04/2022 to 10/29/2026
Signature product of Perrigo Company plc

This indicator measures the proportion of long-term liabilities within the equity structure, determining the degree of financial leverage and the company's resilience to long-term credit risks. For Perrigo Company plc (PRGO), the regionalization of raw material supply chains requires capital expenditures; therefore, analyzing the ratio of long-term loans to equity allows for an assessment of how effectively the company finances its logistical transformation without risking default.

Analysis of competing companies

Haleon PLC - Long-Term Liabilities to Equity|Long-Term Debt to Capital KVUE|VRNA (Verona Pharma Inc.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital MENS (Jyong Biotech Ltd)|Long-Term Debt to Capital ligand.com LGND|AMRX - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient ALVO (Alvotech S.A.)|Liquidia Technologies (LQDA) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Galapagos Corp|ANIP (ANI Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Debt to Capital mannkindcorp.com|Long-Term Debt to Equity Ratio AMPH (Amphastar Pharmaceuticals, Inc.)|PCRX (Pacira Pharmaceuticals) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity ARS Pharma SPRY|Theravance Corp (TBPH) - Long-Term Liabilities to Capital|AQST: Long-Term Debt to Equity Ratio|scPharmaceuticals Inc. - Long-Term Loans to Capital Ratio|TECX: Long-Term Debt to Capital|Tonix Pharma - Long-Term Debt to Capital Coefficient|SXTC (SXT Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Eupraxia Pharma EPRX|Long-Term Debt to Equity BioHarvest Sciences (BHST)|EXOZ (invizyne.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Oramed Pharmaceuticals Inc. ORMP|ENTX (Entera Bio Ltd) - Long-Term Liabilities to Equity|MindWalk - Long-Term Debt to Capital|Long-Term Liabilities to Capital ABVC BioPharma, Inc|Cumberland Pharmaceuticals (CPIX) - Long-Term Debt to Equity|quantumbiopharma.com - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity FibroGen|TELO: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital RANI|Ratio of Long-Term Indebtedness to Capital synergychc.com|Long-Term Debt to Capital RLYB (Rallybio)|Long-Term Indebtedness to Equity Lexaria Bioscience Corp|PULM - Long-Term Debt to Equity|Long-Term Liabilities to Capital Pheton Holdings Ltd|APM (aptorumgroup.com) - Long-Term Debt to Equity Ratio|Lyra Therapeutics Inc - Long-Term Debt to Capital Coefficient|IBO (Impact BioMedical Inc) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio TNF Pharma (TNFA)|Long-Term Debt to Equity cbdMD, Inc. (YCBD)|PRFX - Long-Term Liabilities to Capital|Long-Term Debt to Equity Altamira Therapeutics Ltd. CYTO|LIPO - Long-Term Debt to Equity Ratio|OPTN - Long-Term Debt to Equity|Long-Term Liabilities to Equity PIRS|PROC: Long-Term Debt to Capital|Petros Pharmaceuticals Inc (PTPI) - Long-Term Debt to Capital|Long-Term Debt to Equity Qilian International Holding Group Limited|Long-Term Debt to Capital Ratio SLRN (ACELYRIN Inc.)|Long-Term Debt to Equity Ratio TFFP (TFF Pharmaceuticals)